CompletedNCT00718510
L-arginine added to usual care for schizophrenia
About this title
Read the official source — NCT00718510Medication studyAges 18–65Canada
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- EdmontonSee all locations and recruitment
Study information
Study start dateSeptember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- University of Alberta
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00718510
- Official title
Show the full official title
A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Edmonton
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Alberta, a university.
Did this study involve medication?
Yes. The study involved medication, including L-Arginine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
